Investor Presentation First Nine Months of 2023
32
Investor presentation
First nine months of 2023
Novo NordiskⓇ
Pipeline supports significant growth opportunities across all four
strategic focus areas
PHASE 1
NN1845 GSI
NN1471
Pumpinsulin
NN9041 - DNA Immunotherapy
NN9541-OW GLP-1/GIP co-agonist
NN9904 Once weekly oral sema
NN9487 - Oral Amycretin
NN9490 Sc Amycretin
NN6582 - LXR(a) in MASH
NN6581 - MARC1 in MASH
NN9003 - Stem Cells in HF
NN9001 - Stem Cells in PD
NN6491 - Anti-ANGPTL3 in CVD
PHASE 2
NN9440-INV-202
NN7533 Ndec in SCD
NN7536 Etavopivat in Beta thalassemia NN9388 - Cagrisema
NN9931 - Gilead in MASH
NN9500 FGF-21 in MASH
-
-
NN6021 Belcesiran in AATLD
NN6019-ATTR Cardiomyopathy
PHASE 3
NN1535- Icosema
SUBMITTED
NN1436 Insulin Icodec
NN9924 - Oral Semaglutide 25 and 50 mg¹
-
APPROVED
TresibaⓇ
NN7415 Concizumab in HwI, HA/HB2 XultophyⓇ
SELECT - Semaglutide 2.4 mg CVOT in
obese population
Levemir®
NN9536 Semaglutide 7.2 mg
NN9838 Cagrisema
RyzodegⓇ
NovoMixⓇ
FiaspⓇ
NovoRapidⓇ
NN9932 Oral Semaglutide 25 and 50 mg obesity
NN9931
Semaglutide 2.4 mg in MASH
NN6535 Oral Semaglutide 14.0 mg in AD
NN6018
Ziltivekimab in ASCVD
NN6018 Ziltivekimab in HFPEF
NN6023
-
NN7769
NN7535
Ocedurenone in CKD
Mim8 in HA
Etavopivat in SCD
Other PHASE 3 trials
-
SOUL Oral semaglutide 14.0 mg CVOT
FOCUS Semaglutide 1.0 mg in diabetic retinopathy
FLOW Semaglutide 1.0 mg in CKD
STRIDE Semaglutide 1.0 mg in PAD
STEP Semaglutide 2.4 mg in HFPEF and T2D
RybelsusⓇ
Ozempic
Ⓡ3
VictozaⓇ
WegovyⓇ
SaxendaⓇ
NovoSevenⓇ
NovoEight®
EsperoctⓇ
NovoThirteenⓇ
Refixia®
AlhemoⓇ4
RivflozaⓇ5
Diabetes care
Obesity care
Rare blood disorders
Rare endocrine disorders
Other serious chronic diseases
Norditropin®
Sogroya®
1Submitted to EMA; 2Submitted to EU for HwI, to Japan for HA/HB; 3Higher doses of injectable semaglutide (8 mg and 16 mg) tested in phase 2; 4Approved in Canada (HAWI/HBWI), Australia (HAWI/HBWI), Switzerland (HAWI/HBWI) and Japan (HAWI/HBWI);5
Approved for PH1. AATLD: Alpha-1 Antitrypsin Deficiency-associated Liver Disease; AD: Alzheimer's Disease; ANGPTL3: Angiopoietin-like protein 3; ASCVD: Atherosclerotic Cardiovascular Disease; ATTR: Transthyretin amyloidosis; CKD: chronic kidney disease;
CVOT: Cardiovascular outcome trial; FGF-21: Fibroblast growth factor 21; GHD: Growth hormone disorder; GSI: Glucose Sensitive Insulin; HA: Haemophilia A; HF: Heart failure; HFPEF: heart failure with preserved ejection fraction; HwI: Haemophilia with inhibitors;
JP: Japan; LXR(a): Liver X receptor alpha; MARC1: Mitochondrial amidoxime reducing component 1; MASH: Metabolic dysfunction-associated steatohepatitis; MDS: myelodysplastic syndrome; PAD: Peripheral arterial disease; PD: Parkinson's Disease; PH: Primary
hyperoxaluria; SCD: Sickle cell disease; Sema: Semaglutide; US: United StatesView entire presentation